StrataMRD is a tumor-informed, personalized circulating tumor DNA (ctDNA) test to detect tumor recurrence and monitor treatment effectiveness for patients. The investigational test is available through the Sentinel Trial. The ultra-sensitive, individualized blood test leverages multiplexed PCR amplicon-based NGS of blood-based ctDNA to monitor for a personalized set of informative mutations.